vs
Side-by-side financial comparison of Addex Therapeutics Ltd. (ADXN) and Sono Group N.V. (SSM). Click either name above to swap in a different company.
Sono Group N.V. is the larger business by last-quarter revenue ($52.9K vs $33.0K, roughly 1.6× Addex Therapeutics Ltd.).
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative allosteric modulator therapies for underserved neurological and psychiatric disorders. It operates in global biopharmaceutical markets, with a pipeline targeting rare and common central nervous system conditions to address unmet patient needs.
Sonos, Inc. is an American audio equipment manufacturer headquartered in Santa Barbara, California. The company was founded in 2002 by John MacFarlane, Craig Shelburne, Tom Cullen, and Trung Mai.
ADXN vs SSM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $33.0K | $52.9K |
| Net Profit | $-1.7M | — |
| Gross Margin | — | 28.6% |
| Operating Margin | -2320.0% | — |
| Net Margin | -5256.7% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $52.9K | ||
| Q3 25 | $33.0K | $52.9K | ||
| Q2 25 | — | $27.0K | ||
| Q1 25 | — | $28.1K | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 |
| Q4 25 | — | — | ||
| Q3 25 | $-1.7M | $-1.5M | ||
| Q2 25 | — | $-877.0K | ||
| Q1 25 | — | $9.5M | ||
| Q3 24 | — | $-10.3M | ||
| Q2 24 | — | $-1.6M |
| Q4 25 | — | 28.6% | ||
| Q3 25 | — | 63.3% | ||
| Q2 25 | — | 24.0% | ||
| Q1 25 | — | 23.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -2320.0% | -3206.1% | ||
| Q2 25 | — | -7088.0% | ||
| Q1 25 | — | -6410.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -5256.7% | -2838.8% | ||
| Q2 25 | — | -3248.0% | ||
| Q1 25 | — | 33988.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $222.5K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-115.6K |
| Total Assets | — | $1.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $222.5K | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $366.1K | ||
| Q1 25 | — | $865.1K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | $-115.6K | ||
| Q3 25 | — | $2.7M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-15.0M | ||
| Q3 24 | — | $-19.2M | ||
| Q2 24 | — | $-8.9M |
| Q4 25 | — | $1.5M | ||
| Q3 25 | — | $4.3M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $2.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7K | $-7.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.3M | ||
| Q3 25 | $-1.7K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-2.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
